Esindajate nimetamine
| Dokumendiregister | Sotsiaalministeerium |
| Viit | 1.4-2/133-1 |
| Registreeritud | 16.01.2025 |
| Sünkroonitud | 17.01.2025 |
| Liik | Sissetulev kiri |
| Funktsioon | 1.4 EL otsustusprotsess ja rahvusvaheline koostöö |
| Sari | 1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik) |
| Toimik | 1.4-2/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | EV alaline esindus EL juures |
| Saabumis/saatmisviis | EV alaline esindus EL juures |
| Vastutaja | Agne Nettan-Sepp (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond) |
| Originaal | Ava uues aknas |
Failid
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
HE the Ambassador Permanent Representation of Estonia Rue Guimard 11–13 B-1040 Bruxelles BELGIUM 15 January 2025 EMA/15991/2025 Executive Director
Your Excellency,
Subject: Nomination of representatives in the Management Board (MB) of the European Medicines Agency
In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency’s Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries.
The three-year mandate of the representative listed below will be expiring soon. I, therefore, invite you to nominate a new representative for a new three-year mandate starting from the date indicated below. In case you are nominating a new representative and a different start date for the mandate is envisaged, please inform me accordingly.
Alar Irs Alternate 18 May 2025
When submitting the nomination, note that the Agency’s Management Board has determined that members and alternates should meet conditions concerning their declarations of interests as described in the policy on the handling of competing interests of Management Board members. This policy is published on the EMA website.
Please address the nomination to my attention at [email protected] (with copy to [email protected]), indicating full contact details for the nominee and a start date of the mandate (if no particular start date of the mandate is mentioned, the nominee’s will start their mandate on date of receipt of nomination + 1 day). Also, any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence.
Yours faithfully,
Emer Cooke Executive Director
From: Esindus EL juures üldaadress <[email protected]>
Sent: Thu, 16 Jan 2025 08:07:21 +0000
To: Tiiu Noobel <[email protected]>
Subject: FW: Estonia - 2025-15-01 - Nomination invitation letter for an alternate member to the Management Board
From: Oliver-Diaz Olga <[email protected]>
Sent: Wednesday, January 15, 2025 12:40 PM
To: Esindus EL juures üldaadress <[email protected]>
Cc: Kiisk Katrin <[email protected]>; Irs Alar <[email protected]>
Subject: Estonia - 2025-15-01 - Nomination invitation letter for an alternate member to the Management Board
Your Excellency,
Please find attached a letter signed by the European Medicines Agency's Executive Director requesting the nomination of a representative to the Management Board.
You are kindly invited to address nominations to the European Medicines Agency’s Executive Director – Ms Emer Cooke - at [email protected] (with copy to [email protected]).
Nominees will be subject to a pre-screening of any declared competing interest in line with the Agency's policy on handling of competing interests. In case of a negative outcome, the Agency will provide feedback of this screening to the nominating authority for subsequent consideration.
Do not hesitate to contact me should you have any questions regarding this request for nomination.
Sincerely yours,
Olga Oliver-Díaz
Management Board Secretariat
European Medicines Agency
Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands
Telephone +31 (0)88 781 7154
[email protected] | www.ema.europa.eu | For directions, see How to find us
Follow us: 
This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.
Classified as confidential by the European Medicines Agency
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
HE the Ambassador Permanent Representation of Estonia Rue Guimard 11–13 B-1040 Bruxelles BELGIUM 15 January 2025 EMA/15991/2025 Executive Director
Your Excellency,
Subject: Nomination of representatives in the Management Board (MB) of the European Medicines Agency
In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency’s Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries.
The three-year mandate of the representative listed below will be expiring soon. I, therefore, invite you to nominate a new representative for a new three-year mandate starting from the date indicated below. In case you are nominating a new representative and a different start date for the mandate is envisaged, please inform me accordingly.
Alar Irs Alternate 18 May 2025
When submitting the nomination, note that the Agency’s Management Board has determined that members and alternates should meet conditions concerning their declarations of interests as described in the policy on the handling of competing interests of Management Board members. This policy is published on the EMA website.
Please address the nomination to my attention at [email protected] (with copy to [email protected]), indicating full contact details for the nominee and a start date of the mandate (if no particular start date of the mandate is mentioned, the nominee’s will start their mandate on date of receipt of nomination + 1 day). Also, any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence.
Yours faithfully,
Emer Cooke Executive Director
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. |
Edastan Euroopa Ravimiameti kirja. Vastama peab EV AEEL juures kaudu. Palun saatke info [email protected], koopiasse [email protected].
EV AEEL juures reg. number: 14-4/32
Reg. kuupäev: 16.01.2025
Sisu: Eesti esindajate nimetamine Euroopa Ravimiameti (EMA) haldusnõukogusse / Nomination of representatives (alternate) in the Management Board (MB) of the European Medicines Agency
--
Heade soovidega
Tiiu Noobel
sekretär, EV alaline esindus EL juures
+32 2227 4337
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
HE the Ambassador Permanent Representation of Estonia Rue Guimard 11–13 B-1040 Bruxelles BELGIUM 15 January 2025 EMA/15991/2025 Executive Director
Your Excellency,
Subject: Nomination of representatives in the Management Board (MB) of the European Medicines Agency
In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency’s Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries.
The three-year mandate of the representative listed below will be expiring soon. I, therefore, invite you to nominate a new representative for a new three-year mandate starting from the date indicated below. In case you are nominating a new representative and a different start date for the mandate is envisaged, please inform me accordingly.
Alar Irs Alternate 18 May 2025
When submitting the nomination, note that the Agency’s Management Board has determined that members and alternates should meet conditions concerning their declarations of interests as described in the policy on the handling of competing interests of Management Board members. This policy is published on the EMA website.
Please address the nomination to my attention at [email protected] (with copy to [email protected]), indicating full contact details for the nominee and a start date of the mandate (if no particular start date of the mandate is mentioned, the nominee’s will start their mandate on date of receipt of nomination + 1 day). Also, any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence.
Yours faithfully,
Emer Cooke Executive Director
From: Esindus EL juures üldaadress <[email protected]>
Sent: Thu, 16 Jan 2025 08:07:21 +0000
To: Tiiu Noobel <[email protected]>
Subject: FW: Estonia - 2025-15-01 - Nomination invitation letter for an alternate member to the Management Board
From: Oliver-Diaz Olga <[email protected]>
Sent: Wednesday, January 15, 2025 12:40 PM
To: Esindus EL juures üldaadress <[email protected]>
Cc: Kiisk Katrin <[email protected]>; Irs Alar <[email protected]>
Subject: Estonia - 2025-15-01 - Nomination invitation letter for an alternate member to the Management Board
Your Excellency,
Please find attached a letter signed by the European Medicines Agency's Executive Director requesting the nomination of a representative to the Management Board.
You are kindly invited to address nominations to the European Medicines Agency’s Executive Director – Ms Emer Cooke - at [email protected] (with copy to [email protected]).
Nominees will be subject to a pre-screening of any declared competing interest in line with the Agency's policy on handling of competing interests. In case of a negative outcome, the Agency will provide feedback of this screening to the nominating authority for subsequent consideration.
Do not hesitate to contact me should you have any questions regarding this request for nomination.
Sincerely yours,
Olga Oliver-Díaz
Management Board Secretariat
European Medicines Agency
Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands
Telephone +31 (0)88 781 7154
[email protected] | www.ema.europa.eu | For directions, see How to find us
Follow us:
This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.
Classified as confidential by the European Medicines Agency
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
HE the Ambassador Permanent Representation of Estonia Rue Guimard 11–13 B-1040 Bruxelles BELGIUM 15 January 2025 EMA/15991/2025 Executive Director
Your Excellency,
Subject: Nomination of representatives in the Management Board (MB) of the European Medicines Agency
In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency’s Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries.
The three-year mandate of the representative listed below will be expiring soon. I, therefore, invite you to nominate a new representative for a new three-year mandate starting from the date indicated below. In case you are nominating a new representative and a different start date for the mandate is envisaged, please inform me accordingly.
Alar Irs Alternate 18 May 2025
When submitting the nomination, note that the Agency’s Management Board has determined that members and alternates should meet conditions concerning their declarations of interests as described in the policy on the handling of competing interests of Management Board members. This policy is published on the EMA website.
Please address the nomination to my attention at [email protected] (with copy to [email protected]), indicating full contact details for the nominee and a start date of the mandate (if no particular start date of the mandate is mentioned, the nominee’s will start their mandate on date of receipt of nomination + 1 day). Also, any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence.
Yours faithfully,
Emer Cooke Executive Director
